Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process

Journal of Supercritical Fluids

Volumn 51, Issue 3, 2010, Pages 412-419

  Zhao, Xiuhua ^a   Zu, Yuangang ^a   Li, Qingyong ^a   Wang, Meixiang ^a   Zu, Baishi ^a   Zhang, Xiaonan ^a   Jiang, Ru ^a   Zu, Chunlin ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Camptothecin; Characterization; Micronization; Nanosuspension; Preparation; Supercritical antisolvent

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECINS; MICRONIZATIONS; NANO-SUSPENSIONS; SUPERCRITICAL ANTISOLVENTS;

ANALYSIS OF VARIANCE (ANOVA); ATOMIC SPECTROSCOPY; BODY FLUIDS; CARBON DIOXIDE; CHARGE TRAPPING; CHROMATOGRAPHIC ANALYSIS; DIFFERENTIAL SCANNING CALORIMETRY; DIMETHYL SULFOXIDE; FOURIER TRANSFORM INFRARED SPECTROSCOPY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAGNETOPLASMA; MASS SPECTROMETRY; ORGANIC POLYMERS; ORGANIC SOLVENTS; PHOTODEGRADATION; PRESSURE EFFECTS; REGRESSION ANALYSIS; SCANNING ELECTRON MICROSCOPY; SYNTHETIC APERTURE SONAR; X RAY DIFFRACTION; X RAY DIFFRACTION ANALYSIS;

SUPERCRITICAL FLUID EXTRACTION;

EID: 73149083704     PISSN: 08968446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.supflu.2009.10.004     Document Type: Article

References (28)

1. Koo O.M., Rubinstein I., and Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1 (2005) 77-84
2. Clements M.K., Wasi S., and Daoud S.S. Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro. Anticancer Drugs 7 (1996) 851-857
3. Oberlies N.H., and Kroll D.J. Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. 67 (2004) 129-135
4. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., and Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246 (1989) 1046-1048
5. Hertzberg R.P., Caranfa M.J., and Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28 (1989) 4629-4638
6. Cheng Y.Y., Li M.H., and Xu T.W. Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies. Eur. J. Med. Chem. 43 (2008) 1791-1795
7. Moertel C.G., Schutt A.J., Reitemeier R.J., and Hahn R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 156 (1972) 95-101
8. Watanabe M., Kawano K., Yokoyama M., Opanasopit P., Okano T., and Maitani Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int. J. Pharm. 308 (2006) 183-189
9. Zhang X.X., Pan W.S., Gan L., Zhu C.L., and Gan Y. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Acta Pharmacol. Sin. 29 (2008) 1391-1398
10. Zhang L.Y., Hu Y., Jiang X.Q., Yang C.Z., Lu W., and Yang Y.H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J. Control. Release 96 (2004) 135-148
11. Cortesi R., Esposito E., Maietti A., Menegatti E., and Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm. 159 (1997) 95-103
12. Kang J.C., Kumar V., Yang D., Chowdhury P.R., and Hohl R.J. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur. J. Pharm. Sci. 15 (2002) 163-170
13. Schneider T., Zhao H., Jackson J.K., Chapman G.H., Dykes J., and Häfeli U.O. Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin-loaded polymer microspheres. J. Pharm. Sci. 97 (2008) 4943-4954
14. Moon C., Kwon Y.M., Lee W.K., Park Y.J., Chang L.C., and Yang V.C. A novel polyrotaxane-based intracellular delivery system for camptothecin: In vitro feasibility evaluation. J. Biomed. Mater. Res. A 84A (2008) 238-246
15. Inoue K., Kumazawa E., Kuga H., Susaki H., Masubuchi N., and Kajimura T. CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv. Exp. Med. Biol. 519 (2003) 145-153
16. Moschwitzer J., Achleitner G., Pomper H., and Muller R.H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 58 (2004) 615-619
17. Reverchon E., De Marco I., and Torino E. Nanoparticles production by supercritical antisolvent precipitation: a general interpretation. J. Supercrit. Fluids 43 (2007) 126-138
18. Lee L.Y., Wang C.H., and Smith K.A. Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. J. Control. Release 125 (2008) 96-106
19. 2 antisolvent with enhanced mass transfer. Int. J. Pharm. 228 (2001) 19-31
20. Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H.H., and Hwang S.J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 69 (2008) 454-465
21. Reverchon E., Della Porta G., Sannino D., and Ciambelli P. Supercritical antisolvent precipitation of nanoparticles of a zinc oxide precursor. Powder Technol. 102 (1999) 127-134
22. Andreatta A.E., Florusse L.J., Bottini S.B., and Peters C.J. Phase equilibria of dimethyl sulfoxide (DMSO) + carbon dioxide, and DMSO + carbon dioxide + water mixtures. J. Supercrit. Fluids 44 (2008) 273-278
23. Chiu H.Y., Jung R.F., Lee M.J., and Lin H.M. Vapor-liquid phase equilibrium behavior of mixtures containing supercritical carbon dioxide near critical region. J. Supercrit. Fluids 42 (2007) 60-68
24. Reverchon E., and Adami R. Nanomaterials and supercritical fluids. J. Supercrit. Fluids 37 (2006) 1-22
25. Kim J.S., Kim M.S., Park H.J., Jin S.J., Lee S., and Hwang S.J. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int. J. Pharm. 359 (2008) 211-219
26. Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H., and Hwang S.J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process, Eur. J. Pharm. Biopharm. 69 (2008) 454-465
27. Jun S.W., Kim M.S., Kim J.S., Park H.J., Lee S., Woo J.S., and Hwang S.J. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 66 (2007) 413-421
28. Majerik V., Charbit G., Badens E., Horvath G., Szokonya L., Bosc N., and Teillaud E. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. J. Supercrit. Fluids 40 (2007) 101-110